Please login to the form below
patisiran
This page shows the latest patisiran news and features for those working in and with pharma, biotech and healthcare.
Orphan drugs dominate FDA's record-breaking year
Other highlights of the year included Alnylam’s hereditary ATTR amyloidosis drug Onpattro (patisiran) becaming the first RNA interference (RNAi) therapy to get a green light from the FDA.
Latest news
-
NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
The draft highly specialised technologies guidance on Tegsedi (inotersen) and Onpattro (patisiran) concluded that both treatments slows progression of the disease and improve quality of life, but says uncertainty around these ... Commenting on the draft
-
Alnylam gets EU nod for Onpattro amid pricing backlash
The EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the ... intravenous injection of patisiran every three
-
ICER says Alnylam’s Onpattro should cost 90%-95% less
In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’ antisense candidate Tegsedi (inotersen) which is due for an FDA
-
Alnylam claims RNAi milestone with Onpattro approval
Alnylam is however modelling an average $345, 000 annual cost after discounts, and is also offering a money back guarantee for insurers in the form of a rebate if patisiran ... John Maraganore has led Alnylam since 2002. Alnylam’s chief executive –
-
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals
Three new biosimilars also gets the green light. The EMA’s main advisory committee backed the approval of 16 drugs at its meeting ahead of the weekend, including Alnylam’s patisiran ... The Committee for Medicinal Products for Human Use (CHMP) gave a
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Its pivotal APOLLO trial showed nearly all patisiran-treated patients saw the disease halted or slowed, with more than half seeing their neuropathy reversed.
-
Deal Watch table for January 2014
Alnylam/ Genzyme. Extended agreement. Additional markets for patisiran and 3 pipeline products with option to all rare disease products.
-
Pharma deals during January 2014
The original deal was forged back in 2012 when Genzyme gained access to patisiran for the treatment of transthyretin familial amyloid polyneuropathy in Japan and other Asian markets.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director
-
Competitive Salary Offered
-
Business Director
-
Competitive Salary Offered
-
Senior Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Global Business Development Director – Health Education
-
excellent commission
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- GSK upbeat on its return to oncology market
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- AZ’s Sean Bohen to exit after business overhaul; report
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...
Latest intelligence
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
- Escaping the spin cycle of sub-optimal launch
- ...
Quick links
Infographics
